Biosergen AB (BIOSGN.ST)
SEK 0.32
(6.6%)
SEK 0.32
(6.6%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -27.03 Million SEK | 20.28% |
| 2022 | -33.91 Million SEK | 1.87% |
| 2021 | -34.55 Million SEK | -378.51% |
| 2020 | -7.22 Million SEK | -33.24% |
| 2019 | -5.42 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -6.89 Million SEK | -6.55% |
| 2024 Q2 | -5.72 Million SEK | 16.9% |
| 2023 Q2 | -8.03 Million SEK | -59.82% |
| 2023 Q4 | -6.46 Million SEK | 13.86% |
| 2023 Q3 | -7.51 Million SEK | 6.49% |
| 2023 Q1 | -5.02 Million SEK | 22.87% |
| 2023 FY | -27.03 Million SEK | 20.28% |
| 2022 Q1 | -5 Million SEK | 49.7% |
| 2022 FY | -33.91 Million SEK | 1.87% |
| 2022 Q4 | -6.51 Million SEK | 54.97% |
| 2022 Q3 | -14.46 Million SEK | -81.81% |
| 2022 Q2 | -7.95 Million SEK | -58.85% |
| 2021 Q4 | -9.95 Million SEK | -48.0% |
| 2021 Q2 | -12.55 Million SEK | -51.17% |
| 2021 FY | -34.55 Million SEK | -378.51% |
| 2021 Q1 | -8.3 Million SEK | 0.0% |
| 2021 Q3 | -6.72 Million SEK | 46.4% |
| 2020 FY | -7.22 Million SEK | -33.24% |
| 2019 FY | -5.42 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | 40.967% |
| Biovica International AB (publ) | -124.82 Million SEK | 78.34% |
| Cantargia AB (publ) | -280.02 Million SEK | 90.345% |
| CombiGene AB (publ) | -35.66 Million SEK | 24.193% |
| Cyxone AB (publ) | -22.98 Million SEK | -17.608% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -131.521% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -64.88% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 70.419% |
| Fluicell AB (publ) | -26.55 Million SEK | -1.819% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 78.031% |
| Mendus AB (publ) | -101.61 Million SEK | 73.394% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 27.067% |
| I-Tech AB | 20.2 Million SEK | 233.827% |
| Intervacc AB (publ) | -102.85 Million SEK | 73.713% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -122.93% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 322.179% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -51.07% |
| OncoZenge AB (publ) | -15.9 Million SEK | -70.023% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -6072.831% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 93.035% |
| Lipum AB (publ) | -37.17 Million SEK | 27.277% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 89.124% |
| Ziccum AB (publ) | -21.41 Million SEK | -26.27% |
| BioArctic AB (publ) | 229.24 Million SEK | 111.794% |
| Genovis AB (publ.) | 61.5 Million SEK | 143.963% |
| Camurus AB (publ) | 431.44 Million SEK | 106.267% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 84.797% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 52.417% |
| Aptahem AB (publ) | -11.11 Million SEK | -143.295% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 91.305% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 84.952% |
| Kancera AB (publ) | -64.88 Million SEK | 58.333% |
| Saniona AB (publ) | -95.81 Million SEK | 71.781% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 35.966% |
| AcouSort AB (publ) | -17.08 Million SEK | -58.213% |
| Xintela AB (publ) | -54.08 Million SEK | 50.008% |
| Abliva AB (publ) | -95.5 Million SEK | 71.692% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 601.987% |
| Amniotics AB (publ) | -30.87 Million SEK | 12.417% |
| 2cureX AB (publ) | -32.51 Million SEK | 16.855% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -110.766% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 94.2% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 96.749% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -63.633% |
| Corline Biomedical AB | -1.8 Million SEK | -1394.583% |
| NextCell Pharma AB | -41.95 Million SEK | 35.565% |
| Nanologica AB (publ) | -75.15 Million SEK | 64.026% |
| LIDDS AB (publ) | -40.2 Million SEK | 32.754% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 91.729% |
| BioInvent International AB (publ) | -330.3 Million SEK | 91.815% |
| SynAct Pharma AB | -215.81 Million SEK | 87.472% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 38.628% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -13.902% |
| Alzinova AB (publ) | -16.48 Million SEK | -64.059% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 75.261% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 89.147% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -172.276% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 76.142% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -28.192% |
| Simris Alg AB (publ) | -37.3 Million SEK | 27.524% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 82.195% |